Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II study of fractionated stereotactic body radiotherapy plus gemcitabine/erlotinib for unresectable locally advanced pancreatic cancer
KCT0000158Phase 2Not yet recruiting
- Sponsor
- Seoul St. Mary's Hospital
- Start
- Aug 2011
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, single-arm trial of gemcitabine and erlotinib in pancreatic cancer (PC), sponsored by Seoul St. Mary's Hospital. Planned start Aug 2011; status: not yet recruiting.
02
Drugs
gemcitabineerlotinib
03
Conditions
pancreatic cancer (PC)
Beyond the preview
Go deeper on KCT0000158.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on KCT0000158.